Phase 2 Readout
GLUE: Phase 2 Readout: mrt-6160
December 31, 2026 · mrt-6160. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- December 31, 2026
- Company
- Monte Rosa Therapeutics, Inc. (GLUE)
- Drug
- mrt-6160
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 2 Readout~quarter
Phase 2 Readout: mrt-6160
- Drug
- mrt-6160
- Indication
- immune-mediated diseases